7 months ago
MRK
AnalystsAndrew BaumAndrew Baum's Stock Forecasts
AnalystsAndrew Baum
Analyst Ranking
Top 20%
#985 out of 4995 analysts
Average Return
+14.75%
Win Rate
67%18 out of 27
Risk vs Reward
Poor
Good
Andrew Baum's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Eli Lilly & CoLLY | +145.62% | $318.43 | $782.12 | 2023-03-03 - 2024-03-01 | Strong Buy |
Eli Lilly & CoLLY | +81.04% | $453.59 | $821.19 | 2023-07-26 - 2024-07-25 | Strong Buy |
Eli Lilly & CoLLY | +57.66% | $576.65 | $909.15 | 2023-10-23 - 2024-10-22 | Strong Buy |
Eli Lilly & CoLLY | +45.16% | $230.36 | $334.38 | 2021-09-29 - 2022-09-28 | Strong Buy |
Abbvie IncABBV | +37.74% | $108.22 | $149.06 | 2021-03-12 - 2022-03-11 | Strong Buy |
Andrew Baum Analyst Color
Get additional color on Andrew Baum's coverage of popular stocks
10 months ago
ABBV
a year ago
LLY
2 years ago
LLY
2 years ago
PFE
2 years ago
LLY
2 years ago
MRK
Andrew Baum's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Pfizer IncPFE | 6 | Hold | $26.00 | +0.46% | Maintains | 19 days ago |
Bristol Myers Squibb CoBMY | 8 | Hold | $47.00 | -1.92% | Maintains | 24 days ago |
Merck & Co IncMRK | 10 | Hold | $84.00 | -3.86% | Downgrades | 3 months ago |
Royalty Pharma PLCRPRX | 2 | Strong Buy | $40.00 | +10.13% | Maintains | 10 months ago |
Abbvie IncABBV | 5 | Strong Buy | $215.00 | +2.09% | Maintains | 10 months ago |
Eli Lilly & CoLLY | 5 | Strong Buy | $895.00 | N/A | Maintains | a year ago |
AlvotechALVO | 3 | Hold | $10.00 | N/A | Upgrades | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.